VA
ANRO icon

VR Adviser’s Alto Neuroscience ANRO Stock Holding History

VR Adviser’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Hold
500,000
– – 0.4% 30
2026
Q1 		$11.2M Buy
+500,000
New +$9.27M 0.42% 31

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

VR Adviser's ANRO Position: Q2 2026 in Review

VR Adviser held its Alto Neuroscience (ANRO) position steady in Q2 2026 at 500,000 shares worth $13.2M. The position accounts for 0.4% of the portfolio, ranked #30.

VR Adviser first reported a position in ANRO in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • VR Adviser held 500,000 shares of Alto Neuroscience worth $13.2M as of Q2 2026.
  • VR Adviser left its Alto Neuroscience share count unchanged in Q2 2026.
  • Alto Neuroscience made up 0.4% of VR Adviser's portfolio in Q2 2026, its #30 holding.
  • VR Adviser first reported a position in Alto Neuroscience in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.